Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GMED - GenoMed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: average joe who wrote (126)	5/11/2004 12:27:49 AM
From: Tadsamillionaire	Respond to of 347

Seven Physicians in Amarillo, TX Contract with GenoMed to Distribute the Company's Treatments to Their 21,000 Patients Thursday May 6, 12:05 pm ET ST. LOUIS, May 6 /PRNewswire-FirstCall/ -- GenoMed, Inc. (Pink Sheets: GMED - News), a Next Generation Disease Management(TM) company that uses its expertise in genomics to improve patient outcomes, announced today that Dr. John Young, a leader in his medical community of Amarillo, TX, has convinced seven family physician colleagues to distribute GenoMed's protocols to their patients. Together, they care for over 21,000 patients. ADVERTISEMENT Said Dr. David Moskowitz, GenoMed's Chief Medical Officer and CEO, "I am delighted by Dr. Young's effectiveness in educating his medical community about the superior patient outcomes which GenoMed can deliver to patients with hypertension, diabetes, and emphysema. I look forward to working with these outstanding general practitioners, and salute their courage in embracing the latest in medical genomics to help their patients." About GenoMed GenoMed is leading the medical revolution which medical genomics has already made possible. The Company's business model is as novel as its science. GenoMed's Clinical Outcomes Improvement Program(TM) is available to any patient for the nominal subscription fee of $67 a month ($800 per year). Physicians who participate in GenoMed's Clinical Outcomes Improvement Network(TM) have the satisfaction of delivering cutting-edge medicine while enhancing their clinical revenue. GenoMed is currently marketing its protocol for delaying complications of high blood pressure and diabetes including kidney failure. Hypertension and diabetes affect 80 million Americans, are responsible for two-thirds of deaths in the U.S., and account for a similar proportion of healthcare costs. GenoMed intends to demonstrate cost-savings by keeping patients healthier. Safe Harbor Statement This press release contains forward-looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether these seven physicians are able to recruit any of their patients to subscribe to GenoMed's Clinical Outcomes Improvement Program(TM); (b) our research and development being subject to economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. biz.yahoo.com -------------------------------------------------------------------------------- Source: GenoMed, Inc.

To: average joe who wrote (126)	5/23/2004 12:54:57 PM
From: Tadsamillionaire	Respond to of 347

GenoMed Signs Genotyping Contract with Genome Quebec MONTREAL and ST. LOUIS, May 19, 2004 /PRNewswire-FirstCall via COMTEX/ -- The McGill University and Genome Quebec Innovation Centre has announced the signing of a service agreement with GenoMed (Pink Sheets: GMED), a U.S. company located in St. Louis, Missouri that specializes in using genomics to practice better medicine. The Illumina genotyping solution drove this contract win for Quebec. The McGill University and Genome Quebec Innovation Centre is one of the rare centres in the world to have integrated this exclusive technology. Said David Moskowitz, Chairman and CEO of GenoMed, "Our genotyping consists of two stages: screening a very large number of SNPs, and validating a smaller number of them. Only Illumina's genotyping technology lets us screen tens of thousands of SNPs simultaneously. We think we've gotten literally the best deal in the world by having the Montreal Genome Centre perform this large-scale screening project." In the words of Paul L'Archeveque, President and CEO of Genome Quebec, "This service agreement clearly illustrates the organization's desire to make scientific research more credible by creating a favorable, attractive environment that will make Quebec a centre of research excellence." Its reputation, expertise and high-quality services mean that the McGill University and Genome Quebec Innovation Centre can attract clients from Quebec, the rest of Canada, New England and elsewhere across the U.S. About Genome Quebec Genome Quebec was created to make Quebec a member of the privileged ranks of international leaders in genomics and proteomics research. In combining considerable financial resources with a system for managing major research projects, Genome Quebec represents a new development model that makes it especially possible to support the best teams of researchers from academic, industrial and government settings. Its mission is to mobilize the research and business sectors to continue growing Quebec's presence and role in the life sciences sector. Genome Quebec manages a portfolio worth some $220 million. About GenoMed GenoMed is leading the clinical revolution which medical genomics already makes possible. GenoMed is a Next Generation Disease Management(TM) company whose mission is to improve patient outcomes by identifying the genetic pathways that cause disease. GenoMed has published the only paper in the medical literature showing that regression (prevention) of kidney failure due to high blood pressure and diabetes can be achieved. High blood pressure and diabetes affect 80 million Americans. Safe Harbor Statement This press release contains forward looking statements, including those statements pertaining to GenoMed, Inc.'s (the Company's) finances and treatments. The words or phrases "ought to," "should," "could," "may," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ materially from those projected in the forward looking statements as a result of a number of risks and uncertainties, including but not limited to: (a) whether our research and development is fully funded; and (b) our research and development being subject to other economic, regulatory, governmental, and technological factors. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, we specifically disclaim any obligation to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement. SOURCE GenoMed CONTACT: Marie-Kym Brisson, Director, Communications and Public Relations of Genome Quebec, +1-514-398-0668, mkbrisson@genomequebec.ca , or David W. Moskowitz, MD, CEO of GenoMed, Inc., +1-314-977-0115, dwmoskowitz@genomedics.com URL: genomedics.com prnewswire.com pinksheets.com